Synthetic Approaches to a Key Pyridone-carboxylic Acid Precursor Common to the HIV-1 Integrase Strand Transfer Inhibitors Dolutegravir, Bictegravir, and Cabotegravir

被引:2
|
作者
Mahajan, Pankaj S. [1 ]
Burke Jr, Terrence R. [1 ]
机构
[1] NCI, Chem Biol Lab, Ctr Canc Res, NIH, Frederick, MD 21702 USA
基金
美国国家卫生研究院;
关键词
pyridone-carboxylic acid; integrase strand transfer inhibitors; synthetic route; regioselectivity; ester hydrolysis; Dolutegravir; Bictegravir; Cabotegravir; CHELATION;
D O I
10.1021/acs.oprd.3c00063
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Dolutegravir (DTG), Bictegravir (BIC), and Cabotegravir (CAB) are the second-generation integrase strand transfer inhibitors (INSTIs) that have been FDA-approved for the treatment of HIV-1 infection. Preparation of these INSTIs utilizes the common intermediate 1-(2,2-dimethoxyethyl)-5-methoxy-6-(methoxycarbonyl)-4-oxo-1,4-dihydropyridine-3-carboxylic acid (6). Presented herein is a literature and patent review of synthetic routes used to access the pharmaceutically important intermediate 6. The review highlights the ways in which small fine-tuned synthetic modifications have been used to achieve good yields and regioselectivity of ester hydrolysis.
引用
收藏
页码:847 / 853
页数:7
相关论文
共 29 条
  • [21] Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-naive individuals
    Margot, Nicolas A.
    Ram, Renee R.
    White, Kirsten L.
    Abram, Michael E.
    Callebaut, Christian
    JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (12) : 2188 - 2194
  • [22] Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen
    Santoro, Maria M.
    Fornabaio, Chiara
    Malena, Marina
    Galli, Laura
    Poli, Andrea
    Menozzi, Marianna
    Zazzi, Maurizio
    White, Kirsten L.
    Castagna, Antonella
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (01)
  • [23] Selectivity for strand-transfer over 3′-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme-DNA interactions in the active site
    Metifiot, Mathieu
    Johnson, Barry C.
    Kiselev, Evgeny
    Marler, Laura
    Zhao, Xue Zhi
    Burke, Terrence R., Jr.
    Marchand, Christophe
    Hughes, Stephen H.
    Pommier, Yves
    NUCLEIC ACIDS RESEARCH, 2016, 44 (14) : 6896 - 6906
  • [24] Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors
    Yoshinaga, Tomokazu
    Seki, Takahiro
    Miki, Shigeru
    Miyamoto, Tadashi
    Suyama-Kagitani, Akemi
    Kawauchi-Miki, Shinobu
    Kobayashi, Masanori
    Sato, Akihiko
    Stewart, Eugene
    Underwood, Mark
    Fujiwara, Tamio
    ANTIVIRAL RESEARCH, 2018, 152 : 1 - 9
  • [25] Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors
    Hachiya, Atsuko
    Kirby, Karen A.
    Ido, Yoko
    Shigemi, Urara
    Matsuda, Masakazu
    Okazaki, Reiko
    Imamura, Junji
    Sarafianos, Stefan G.
    Yokomaku, Yoshiyuki
    Iwatani, Yasumasa
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (08)
  • [26] Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism
    Savinelli, Stefano
    Newman, Ellen
    Mallon, Patrick W. G.
    CURRENT HIV/AIDS REPORTS, 2024, 21 (06) : 293 - 308
  • [27] Human pharmacokinetics prediction with an in vitro-in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection
    Subramanian, Raju
    Wang, Jianhong
    Murray, Bernard
    Custodio, Joseph
    Hao, Jia
    Lazerwith, Scott
    MacLennan Staiger, Kelly
    Mwangi, Judy
    Sun, Hailing
    Tang, Jennifer
    Wang, Kelly
    Rhodes, Gerry
    Wijaya, Samantha
    Zhang, Heather
    Smith, Bill J.
    XENOBIOTICA, 2022, 52 (12) : 1020 - 1030
  • [28] Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study
    Lagi, F.
    Baldin, G.
    Colafigli, M.
    Capetti, A.
    Madeddu, G.
    Kiros e Un, S. Tekle
    Di Giambenedetto, S.
    Sterrantino, G.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2019, 54 (04) : 487 - 490
  • [29] Predictive Efficacy of Dual Therapies Combining Integrase Strand Transfer Inhibitors with Second-Generation Non-Nucleoside Reverse Transcriptase Inhibitors Following HIV-1 Treatment Failure in Cameroon: Implications for the Use of a Long-Acting Therapeutic Strategy in Low- and Middle-Income Countries
    Gouissi Anguechia, Davy-Hyacinthe
    Bouba, Yagai
    Semengue, Ezechiel Ngoufack Jagni
    Ka'e, Aude Christelle
    Takou, Desire
    Ambe Chenwi, Collins
    Beloumou, Grace
    Nka, Alex Durand
    Basseck Wome, Ulrich Roland
    Santoro, Maria Mercedes
    Ceccherini-Silberstein, Francesca
    Chatte, Adawaye
    Montesano, Carla
    Cappelli, Giulia
    Colizzi, Vittorio
    Ndjolo, Alexis
    Mbanya, Dora
    Ndembi, Nicaise
    Perno, Carlo-Federico
    Fokam, Joseph
    VIRUSES-BASEL, 2024, 16 (12):